Supplements Manufacturer

We formulate, process and pack private label products. Our herbal, vitamins, protein, collagen, and fiber based products are distributed nationally. Powders #1.

[Ocugen @Ocugen]

What is #RetinitisPigmentosa (RP)?

RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

https://t.co/VH9b0oZp6Z

[Supplements Manufacturer @MoreFlax]

@IvandeaGreat 💯🙊🙉🙈

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

https://t.co/VH9b0oZp6Z

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

@Ocugen @drsmusunuri 👏👏👏

https://t.co/Ip2AIVGfzF

[Supplements Manufacturer @MoreFlax]

@Dfwmb123 @Ocugen @drsmusunuri 🤝

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

@Ocugen @drsmusunuri 👏👏👏

https://t.co/Ip2AIVGfzF

[NotEzzAI @NotEzzAI]

https://t.co/DaPrXNBHxm

[TheUrbanFarmer @NattaCop]

$OCGN I get comments questioning price and people’s ability to pay because they don’t understand the why’s, who’s and where’s of drug pricing.

Insurance and payers don’t cover gene therapy because they’re generous, they cover it because the math makes sense.

$1.3 million sounds like a lot, but blindness is not just an eye problem. It becomes a lifelong cost burden. Doctors, specialists, disability, lost income, caregivers, falls, depression, assisted living, benefits, lost productivity, and decades of medical and social costs all tied to vision loss.

When a one time gene therapy like OCU400 can stop someone from going blind, payers are not just paying for a drug. They are paying to avoid the lifetime burden blindness creates.

That’s why these treatments look expensive upfront but still make financial sense. Pay once or keep paying for decades.

This is why approved gene therapies in rare retinal diseases get covered. The burden of blindness is massive, and stopping it is worth billions.🍻

[Supplements Manufacturer @MoreFlax]

@nejatian @Opendoor_God @LiebermanAustin 👏👏👏

[Ocugen @Ocugen]

Ocugen is excited to showcase our innovative modifier #genetherapy platform for inherited retinal and blindness diseases at three conferences this month. @IAmBiotech @NobleCapMkts $OCGN #InvestorRelations

🔗https://t.co/ok0itKrdvM
Noble Capital replay: https://t.co/zLQlXmzENU

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN

https://t.co/MezalmKsVp

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen 👇 ♥️

.... and that is only with #OCU400!!!

[AmlDean @amldean19]

$ocgn #Ocugen Great presentation by Abhi. https://t.co/aBB3h7lTWM

[Ivan @IvandeaGreat]

@amldean19

$OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN

https://t.co/MezalmKsVp

[TheUrbanFarmer @NattaCop]

it’s a cure for RP.

OCU400 is designed to stop the disease at the source. RP destroys the retina over time. If you stop that process, you cured the disease.

Once a cell is completely gone, it’s gone, no drug is bringing back the dead(yet). But sick, damaged, barely functioning cells can start working again, which is why patients are gaining 4+ lines on the eye chart.

So early stage RP, OCU400 stops any damage before it happens.

Late stage RP, it cures the disease and can restore whatever vision is still recoverable.

One shot cure for life, incredible biological breakthrough. 🍻

[Supplements Manufacturer @MoreFlax]

@NattaCop @gotteypakistan Sometimes even financial analysts are making a statement to this treatment as a "CURE"!

[Supplements Manufacturer @MoreFlax]

@BrauneArno @Ocugen 💯

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen 👇 ♥️

.... and that is only with #OCU400!!!

[TheUrbanFarmer @NattaCop]

$OCGN Here’s the conservative math for OCU400, 50% target market, modestly low market penetration.

Ocu400 with “broad RP indication” as a gene agnostic therapy for retinitis pigmentosa:

Total amount of people with broad RP(51%+) in USA and EU:
191,250+ people

Total USA and EU market for Broad RP at $1,350,000 per patient= $258,187,500,000 USD

Total conservative market to catch yearly:
1.5%

Total yearly Revenue for broad RP in USA/EU Markets = $3,872,812,500

5 year revenue projected:
$19,364,062,500 USD

Reasonable market cap valuation for a company with a drug bringing in these numbers = $40b on the bearish side $80b on the bullish side. 🍻

[Arno Braune @BrauneArno]

@MoreFlax @Ocugen And, this is only US&EU.😳